Brian Slomovitz, MD, is director of gynecologic oncology and co-chair of the clinical research committee at Mount Sinai Medical Center in Miami Beach, Florida. He also serves as the clinical trial lead for uterine cancer for GOG Partners.
ROSELLA Trial Offers New Insight Into Global Treatment Strategies for Ovarian Cancer: Brian Slomovitz, MD
Brian Slomovitz, MD, of Mount Sinai Medical Center, compares relacorilant plus nab-paclitaxel with existing treatments for platinum-resistant ovarian cancer and highlights the ROSELLA trial’s global scope.
Relacorilant Plus Nab-Paclitaxel Improves Outcomes in Platinum-Resistant Ovarian Cancer: Brian Slomovitz, MD
Relacorilant combined with nab-paclitaxel (Abraxane) significantly improved progression-free and overall survival in patients with platinum-resistant ovarian cancer in the phase 3 ROSELLA trial, according to Brian Slomovitz, MD, one of the investigators.